Shawn O’Connor
Chief Executive Officer
Good afternoon or evening as the case may be, and welcome to Simulation Plus’ Investor Day. I’d like to thank each of you for joining us, our shareholders, analysts, partners and members of the broader life sciences community. Today is an opportunity to step back from the day-to-day and evaluate where we are, where the industry is headed and where we are positioning Simulations Plus for the future.
Let me briefly outline the agenda for our session. We’ll begin with an overview of our vision, mission and values, followed by company highlights and a look at our history of growth as we approach our 30th anniversary. We’ll then move through the major components of our business, the industry environment and the challenges and opportunities shaping drug development, our software product strategy and fiscal year ’26 roadmap, our scientific services organization, and we’ll conclude with a Q&A session.
This is an important moment for our industry. Biopharma is undergoing significant transformation, the adoption of AI, the shift towards cloud-native scientific computation, the move away from animal testing and the growing reliance on model-informed drug development. These changes are accelerating, and they are redefining the means to develop safe, effective therapies efficiently. It is also a defining moment for Simulations Plus. We are shaping our technology, our services and our operating model to meet the inflection point, strengthening our leadership while building the integrated ecosystem our clients need for future innovation. Today, we’ll take a deeper dive into that ecosystem, our capabilities, our roadmap and the exciting developments
